STOCK TITAN

Lucid Diagnostics Inc. - $LUCD STOCK NEWS

Welcome to our dedicated page for Lucid Diagnostics news (Ticker: $LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lucid Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lucid Diagnostics's position in the market.

Rhea-AI Summary
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) reported a 392% sequential increase in Lucid's quarterly revenue, with Veris Health's expansion efforts underway. The quarterly financial results were presented, and a webcast is scheduled for tomorrow at 8:30 AM EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) reports a 17% increase in Quarterly EsoGuard® test volume and a 392% increase in revenue sequentially. The company's CLIA-certified clinical laboratory performed 2,575 commercial EsoGuard® Esophageal DNA Tests in Q3 2023. Lucid's Q3 revenue was $783K, with operating expenses of $11.9 million. Lucid had cash and cash equivalents of $24.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
-
Rhea-AI Summary
LUCD - Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the launch of EsoGuard 2.0, an enhanced esophageal DNA test with improved performance and lower costs. The company will also host an Investor Day event in New York City on December 13, 2023, to discuss commercial progress and the recent expansion of clinical utility and validity data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, announced that its Chairman and CEO, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will take place at 10:00am EST, and management will be available for one-on-one meetings with investors at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences
-
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call and webcast on November 15, 2023, at 8:30 AM EST. The call will provide a business update and overview of operations and growth strategy by Lishan Aklog, M.D., Chairman and CEO. Dennis McGrath, President and CFO, will discuss the third-quarter 2023 financial results. The webcast will be available on the company's website. Replay will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics Inc. announces two clinical registries collecting real-world data on EsoGuard testing for esophageal precancer. Initial analysis shows excellent concordance with medical decision-making and over 99% technical success. The registries aim to enroll a substantial proportion of all patients undergoing EsoGuard testing and provide valuable clinical utility and validity data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call and webcast on November 14, 2023, at 8:30 AM EST. The call will provide a business update, including an overview of the Company's operations and third-quarter 2023 financial results. The webcast can be accessed on luciddx.com, and the conference call can be accessed by telephone. A replay will be available on the website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary
PAVmed and Lucid Diagnostics to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
Rhea-AI Summary
Lucid Diagnostics Inc. has released positive interim data from the multicenter CLUE study, demonstrating the real-world clinical utility of EsoGuard Esophageal DNA testing. The study shows excellent concordance between test results and subsequent medical decision-making by multiple physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
Lucid Diagnostics Inc.

Nasdaq:LUCD

LUCD Rankings

LUCD Stock Data

47.16M
15.07M
70.39%
3.66%
0.91%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
NEW YORK